About Mirobio
MiroBio: Restoring Balance to the Immune System with Kintsugi-Inspired Approach
MiroBio is a biotechnology company that aims to restore balance to the immune system through its innovative approach inspired by the Japanese art of kintsugi. The company's mission is to develop therapies that can treat autoimmune diseases, cancer, and other immune-related disorders by harnessing the power of natural regulatory T cells (Tregs).
MiroBio's unique approach is based on the idea that just as kintsugi repairs broken pottery with gold or silver lacquer, it is possible to repair damaged immune systems by enhancing Treg function. Tregs are a type of white blood cell that play a critical role in maintaining immune homeostasis and preventing autoimmunity. However, in many diseases, such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, there is an imbalance between Tregs and effector T cells (Teffs), which leads to chronic inflammation and tissue damage.
To address this problem, MiroBio has developed a proprietary platform technology called MIRO-1 that selectively expands functional human Tregs ex vivo. MIRO-1 uses small molecules that activate specific signaling pathways in Tregs while inhibiting those in Teffs. This results in a highly pure population of suppressive Tregs that can be infused back into patients to restore immune tolerance.
MiroBio's lead product candidate based on MIRO-1 is MB101 for treating graft-versus-host disease (GVHD), a life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). GVHD occurs when donor-derived immune cells attack host tissues after HSCT. Current treatments for GVHD involve broad immunosuppression with steroids or other drugs that have significant side effects and limited efficacy.
MB101 has shown promising preclinical data demonstrating its ability to prevent GVHD while preserving graft-versus-leukemia (GVL) effects. MB101 has also shown safety and tolerability in a phase 1 clinical trial in healthy volunteers. MiroBio plans to initiate a phase 1/2a clinical trial of MB101 in patients with acute GVHD in the second half of 2021.
In addition to GVHD, MiroBio is exploring other indications for its Treg-based therapies, including autoimmune diseases such as type 1 diabetes and inflammatory bowel disease (IBD), as well as solid tumors such as melanoma and lung cancer. The company has established collaborations with academic institutions and pharmaceutical companies to advance its research and development efforts.
MiroBio's team consists of experienced scientists, clinicians, and business professionals who are dedicated to advancing the field of Treg immunotherapy. The company is headquartered in Cambridge, UK, with additional offices in London and Boston.
In summary, MiroBio is a biotechnology company that is using a kintsugi-inspired approach to restore balance to the immune system through selective expansion of functional Tregs. Its lead product candidate MB101 has shown promise for treating GVHD while preserving GVL effects. MiroBio's innovative platform technology has potential applications for other immune-related disorders such as autoimmune diseases and cancer. With its talented team and strategic partnerships, MiroBio is poised to make significant contributions to the field of Treg immunotherapy.